Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rasagiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 13/20 | 1.00 |
| ▸ | MAOA | P21397 | 10/20 | 1.00 |
| ▸ | ACHE | P22303 | 3/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rasagiline SCHEMBL74699 | 1.00 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Azilect SCHEMBL332967 | 1.00 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2827373 | 1.00 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL12787613 | 1.00 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Azilect SCHEMBL29605291 | 1.00 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL828802 | 0.98 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2028892 | 0.98 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL5449858 | 0.98 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL316969 | 0.98 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2349557 | 0.98 | MAOB (0.97) | MAOBMAOAACHEBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 606 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310929-B2 | Use of rasagiline for the treatment of restless legs syndrome | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2025-05-27 | — | — | US | claimed |
| CN-110776429-B | Improved preparation method of rasagiline racemic intermediate | 齐鲁制药有限公司 | 2022-12-02 | — | — | CN | claimed |
| CN-110776429-A | Improved preparation method of rasagiline racemic intermediate | 齐鲁制药有限公司 | 2020-02-11 | — | — | CN | claimed |
| EP-2688561-B1 | TRANSDERMAL COMPOSITIONS COMPRISING AN ACTIVE AGENT LAYER AND AN ACTIVE AGENT CONVERSION LAYER | TEIKOKU PHARMA USA INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-9597301-B2 | Propynylaminoindan transdermal compositions | TEIKOKU PHARMA USA, INC. (US) | 2017-03-21 | — | — | US | claimed |
| EP-1954667-B1 | METHODS FOR ISOLATING PROPARGYLATED AMINOINDANS | TEVA PHARMA (IL) | 2017-02-08 | — | — | EP | claimed |
| EP-2563347-B1 | PROPYNYLAMINOINDAN TRANSDERMAL COMPOSITIONS | TEIKOKU PHARMA USA INC (US) | 2016-10-12 | — | — | EP | claimed |
| US-20160184240-A1 | Transdermal Compositions Comprising an Active Agent Layer and An Active Agent Conversion Layer | TEIKOKU PHARMA USA, INC. | 2016-06-30 | — | — | US | claimed |
| US-9119799-B2 | Transdermal compositions comprising an active agent layer and an active agent conversion layer | TEIKOKU PHARMA USA, INC. (US) | 2015-09-01 | — | — | US | claimed |
| US-20150182476-A1 | Propynylaminoindan Transdermal Compositions | TEIKOKU SEIYAKU CO., LTD. (JP) | 2015-07-02 | — | — | US | claimed |
| EP-0812190-A1 | R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, COMPOSITIONS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-12-17 | — | — | EP | claimed |
| EP-0538134-B1 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMA (IL) | 1997-03-12 | — | — | EP | claimed |
| WO-1996037199-A1 | USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-11-28 | — | — | WO | claimed |
| CN-1031995-C | R-enantiomers of N-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them | ORVET BV (NL) | 1996-06-12 | — | — | CN | claimed |
| US-5457133-A | Treating Parkinson's disease, memory disorders, Alzheimer's disease, depression and hyperactive syndrome | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-10-10 | — | — | US | claimed |
| WO-1995011016-A1 | R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDAN, SALTS, COMPOSITIONS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-04-27 | — | — | WO | claimed |
| EP-0436492-B1 | R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it | TEVA PHARMA (IL) | 1994-06-08 | — | — | EP | claimed |
| EP-0538134-A2 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-04-21 | — | — | EP | claimed |
| CN-1062900-A | The R-enantiomorph of N-propargyl-1-aminoidan, its method for making and contain its pharmaceutical composition | ORVET BV (NL) | 1992-07-22 | — | — | CN | claimed |
| EP-0436492-A2 | R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it | Teva Pharmaceutical Industries Limited (IL) | 1991-07-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182476-A1 | Propynylaminoindan Transdermal Compositions | COL14A1, PNN, CUTA | MAOB 3455/4885MAOA 2538/4885ACHE 566/4885 |
| US-12310929-B2 | Use of rasagiline for the treatment of restless legs syndrome | RSU1, PRSS12, PNMT | MAOB 748/4885MAOA 918/4885ACHE 533/4885 |
| US-20160184240-A1 | Transdermal Compositions Comprising an Active Agent Layer and An Active Agent Conversion Layer | CUTA, S100A8, S100B | MAOB 485/4885MAOA 332/4885ACHE 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.